Physician profile
Monish Sheth
NPI 1053699132
$6,694.38
in general payments reported to CMS, 2019-2025
25 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $1,168 · 2021: $796 · 2022: $617 · 2023: $415 · 2024: $1,257 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,300 · Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,300.00 |
| Food and Beverage | $777.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,563.70 | 2024-2025 | Veklury |
| Janssen Pharmaceuticals, INC | $822.95 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $500.40 | 2020-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $449.99 | 2019-2023 | Lifevest |
| Vifor Pharma, INC. | $343.20 | 2020-2024 | Veltassa |
| Pfizer INC. | $296.16 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $284.15 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $180.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.95 | 2019-2022 | |
| Astellas Pharma US INC | $146.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.62 | 2020-2023 | Xifaxan |
| Janssen Scientific Affairs, LLC | $124.98 | 2021 | |
| Allergan, INC. | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.73 | 2020-2024 | |
| Paratek Pharmaceuticals, INC. | $89.34 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $68.17 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $65.13 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $48.56 | 2021 | |
| Shionogi INC | $42.55 | 2021-2023 | Fetroja |
| Dexcom, INC. | $34.83 | 2022-2023 | Dexcom G6 Transmitter |
| Chiesi USA, INC. | $31.92 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.09 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 | |
| Melinta Therapeutics, LLC | $24.37 | 2020 | |
| Novo Nordisk INC | $20.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monish Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.